Braftovi/Mektovi (encorfenib/binimetinib)

pCPA File Number: 21544

Negotiation Status:

Concluded with an LOI

Indication(s):

Braftovi (encorafenib) and Mektovi (binimetinib), in combination, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test

Sponsor/Manufacturer:

Pfizer Canada ULC

CADTH Project Number:

PC0232

pCPA Engagement Letter Issued:

2021-11-03

Negotiation Process Concluded:

2022-07-06